

ASX Market Announcements
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Notice under section 708A(5)(e) of the Corporations Act

Today Adherium Limited (the "Company") lodged an Appendix 3B to announce the issue of 1,277,449 fully paid ordinary shares ("new shares") following the exercise of unlisted options, and also sought quotation of the new shares on ASX.

The Company relies on case 1 in section 708A(5) of the Corporations Act 2001 (Act) in respect of the issue of the new shares.

The Company gives notice under paragraph (5)(e) of section 708A of the Act that:

1. The Company issued the new shares without disclosure to the recipient under Part 6D.2 of the Act;
2. As at the date of this notice the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act (as applicable to the Company); and
 - (b) section 674 of the Act; and
3. As at the date of this notice there is no excluded information (as defined in section 708A(7) of the Act) which is required to be disclosed by the Company.



Rob Turnbull
CFO & Joint Company Secretary
Adherium Limited

[ASX: ADR](#)

ABN

24 605 352 510

Company Overview

Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.

Directors

Dr J Doug Wilson (Chair)
Mr Garth Sutherland (Group CEO)
Prof. John Mills
Mr Jeremy Curnock Cook
Mr Bruce McHarrie
Mr Bryan Mogridge
Dr Bill Hunter

Joint Company Secretaries

Mr Rob Turnbull
Ms Bronwyn Le Grice

Registered Office

Level 12, 15 William Street
Melbourne VIC 3000
Australia

NZ Office

Level 2, 204 Quay Street
Auckland 1010
New Zealand

Investor Relations Contact

Ms Bronwyn Le Grice
+61 424 862 600

Email

investors@adherium.com

Website

www.adherium.com